FXN and cancer: The evaluation of hit compounds in cells from individuals with FRDA and in a humanized GAA repeat expansion mouse model of FRDA identified a number of agents that were able to increase FXN gene expression and frataxin protein, including several anti-cancer compounds, the iron-chelator deferiprone and the phytoalexin resveratrol.